BioCryst Pharmaceuticals BCRX Sale of European ORLADEYO business
Sale of European ORLADEYO business at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDisposalOfBusinessPercentage.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's sale of european orladeyo business.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's sale of european ORLADEYO business?
- BioCryst Pharmaceuticals (BCRX) reported sale of european ORLADEYO business of 1% in Q4 2025.
- What does sale of european ORLADEYO business mean?
- Quantifies the percentage point impact on the effective tax rate attributable to the sale of a specific business segment. This metric isolates the tax-related volatility caused by divestitures rather than core operational performance. It helps investors reconcile the reported tax rate with the underlying business operations.